Utdannelse
Understanding Cardiovascular Risk and Prevention: Insights from Professor Pasquale Perrone-Filardi
Personalized approach in T2D is key for success
The Sanofi webinar ‘Act Now for Impact: Glycemic Control and Beyond’ focuses on recent advancements in treating type 2 diabetes (T2D), emphasizing a personalized approach for better outcomes. Prof. Frank Nobels (Belgium), prof. De Galan (the Netherlands) and Prof Björn Eliasson (Sweden) addressed various aspects of T2D treatment in the present era.
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I
Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262
Why Don’t We Strike Early, Strike Strong?
Prof. Dr. Halvorsen, Prof. Dr. Sinnaeve & Prof. Dr. Martens
Multiple sclerosis progression: time for a new mechanism-driven framework
Paper by Tanja Kuhlmann et al.